Development of an immunocytokine, IL-2-183B2scFv, for targeted immunotherapy of ovarian cancer

Gynecologic Oncology

Volumn 103, Issue 3, 2006, Pages 848-852

  Zhang, Xinyan ^a,b   Feng, Jie ^b   Ye, Xue ^b   Yao, Yu ^b   Zhou, Ping ^b   Chen, Xiaoxin ^a  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Immunocytokine; Interleukin 2; Ovarian cancer

Indexed keywords

IMMUNOCYTOKINE; INTERLEUKIN 2 183B2 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; MONOCLONAL ANTIBODY; OVARIAN CARCINOMA ASSOCIATED 183B2 ANTIGEN; RECOMBINANT INTERLEUKIN 2; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR ANTIGEN;

ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CHO CELL; CONTROLLED STUDY; DRUG SPECIFICITY; DRUG TARGETING; FEMALE; GENE SEQUENCE; GENETIC MANIPULATION; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MICE; OVARIAN NEOPLASMS; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS;

EID: 33751423600     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.05.016     Document Type: Article

References (19)

1. Society A.C. Cancer facts and figures (2005), American Cancer Society, Atlanta
2. Reisfeld R.A., Becker J.C., and Gillies S.D. Immunocytokines: a new approach to immunotherapy of melanoma. Melanoma Res 7 Suppl 2 (1997) S99-S106
3. Rosenberg S.A., Yang J.C., White D.E., and Steinberg S.M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 228 (1998) 307-319
4. Siegel J.P., and Puri R.K. Interleukin-2 toxicity. J Clin Oncol 9 (1991) 694-704
5. Maas R.A., Dullens H.F., and Den Otter W. Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol Immunother 36 (1993) 141-148
6. Rutten V.P., Klein W.R., De Jong W.A., Misdorp W., Den Otter W., Steerenberg P.A., et al. Local interleukin-2 therapy in bovine ocular squamous cell carcinoma. A pilot study. Cancer Immunol Immunother 30 (1989) 165-169
7. Simons J.W., Mikhak B., Chang J.F., DeMarzo A.M., Carducci M.A., Lim M., et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59 (1999) 5160-5168
8. Smith R.M., and Wu G.Y. Hepatocyte-directed gene delivery by receptor-mediated endocytosis. Semin Liver Dis 19 (1999) 83-92
9. Hrouda D., Perry M., and Dalgleish A.G. Gene therapy for prostate cancer. Semin Oncol 26 (1999) 455-471
10. Matsumoto H., Liao S., Arakawa F., Ueno A., Abe H., Awasthi A., et al. Targeting of interleukin-2 to human MK-1-expressing carcinoma by fusion with a single-chain Fv of anti-MK-1 antibody. Anticancer Res 22 (2002) 2001-2007
11. Xu X., Clarke P., Szalai G., Shively J.E., Williams L.E., Shyr Y., et al. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res 60 (2000) 4475-4484
12. Penichet M.L., Dela Cruz J.S., Shin S.U., and Morrison S.L. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Hum Antibodies 10 (2001) 43-49
13. Liu G., Feng J., Zhou P., Huang H., Qian H., Cheng Y., et al. Variable region gene cloning scFv construction, expression and radioimmunoimaging of anti-human ovarian carcinoma McAb. J Peking Univ (Health Science) 33 (2001) 362-365
14. Liu G., Feng J., Zhou P., Huang H., Qian H., Fu T., et al. Cloning, expression and radioimmunoimaging of single domain (VH) gene of anti-human ovarian carcinoma McAb. Chin J Biochem Mol Biol 17 (2001) 350-355
15. Melani C., Figini M., Nicosia D., Luison E., Ramakrishna V., Casorati G., et al. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. Cancer Res 58 (1998) 4146-4154
16. 131I-COC183B2 monoclonal antibody in patients with epithelial ovarian cancer. Chin Med J 104 (1991) 109-115
17. Feng J., Qian H., Cui H., Fu T., Wei P., and Fu Z. Generation and comparison of three monoclonal antibodies in human ovarian epithelial adenocarcinomas. J Beijing Med Univ 21 (1989) 11-13
18. 131I-COC183B2 monoclonal antibody against ovarian carcinoma by intraperitoneal injection. Gynecol Oncol 47 (1992) 216-222
19. Schanzer J.M., Baeuerle P.A., Dreier T., and Kufer P. A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells. Cancer Immun 6 (2006) 4